Thanks to Guidance from the FDA, FDAMA Spells Opportunity
Enlightened Pharma Companies Are Capitalizing on New Clarity from the FDA
Regarding the Sharing of Information with Payers
In the 1990’s, as healthcare costs spiraled out of control, the healthcare industry was inundated with cost-effectiveness analysis studies. While payers were hungry for this type of healthcare economic information (HCEI), regulations strictly limited what pharmaceutical companies could share.